CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 51 enrolled / 51 target
Drug / intervention
Benralizumabdrug
Likely dose
Benralizumab 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04552288
NCT04552288Phase 2CompletedMonitor (0.7/mo)Completion was 23mo ago
CompareCT.gov

Phase II Study of IL-5-receptor-alpha-chain (IL-5Rα) Inhibition With Benralizumab for Eosinophil-Related Cutaneous Adverse Events in Cancer Patients

Memorial Sloan Kettering Cancer Center·interventional·Posted Sep 17, 2020·Updated Jun 1, 2026

In Brief

A Phase 2 clinical trial evaluating Benralizumab for Solid Tumor and 3 related conditions. Completed, enrolled 51 participants across 5 sites.

Signals

Enrolling slower than its timeline implies

Detailed Summary

The purpose of this study is to find out whether the study drug benralizumab is a safe treatment that can reduce the skin side effects caused by cancer treatment by reducing the level of eosinophils in your blood. Reducing the skin side effects of your cancer treatment may improve quality of life and allow participants to continue to receive their usual cancer treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Solid Carcinoma, Solid Tumor, Adult, Hematologic Malignancy
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedSep 17, 2020
Enrollment StartSep 16, 2020
Primary CompletionJul 19, 2024
Study CompletionMay 12, 2026
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 5.8 years ago

Arms & Interventions

Participants with eosinophil-related cutaneous eventsexperimental

Study participants will have grade 2/3 eosinophil-related cutaneous adverse events

Drug: Benralizumab

Interventions

Benralizumabdrug

All eligible patients will receive a benralizumab dose of 30 mg SC administered by a healthcare provider once every 4 weeks for the first 3 doses, followed by once every 8 weeks for 3 additional doses.